X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1037) 1037
Book Chapter (6) 6
Book / eBook (4) 4
Publication (3) 3
Patent (2) 2
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (623) 623
cardiac & cardiovascular systems (536) 536
heart failure (513) 513
male (448) 448
female (441) 441
aged (385) 385
mortality (350) 350
middle aged (341) 341
heart failure - drug therapy (223) 223
prognosis (183) 183
abridged index medicus (175) 175
risk factors (169) 169
heart failure - mortality (156) 156
treatment outcome (144) 144
heart failure - physiopathology (141) 141
cardiovascular (130) 130
morbidity (129) 129
double-blind method (117) 117
hospitalization (113) 113
tetrazoles - therapeutic use (109) 109
kardiologi (106) 106
cardiac and cardiovascular systems (105) 105
drug therapy (104) 104
heart attacks (104) 104
care and treatment (98) 98
outcomes (98) 98
aged, 80 and over (94) 94
survival (94) 94
clinical trials (93) 93
follow-up studies (90) 90
medicine, general & internal (87) 87
risk (87) 87
angiotensin-converting enzyme inhibitors - therapeutic use (86) 86
diabetes (85) 85
trial (85) 85
cardiac patients (83) 83
peripheral vascular disease (80) 80
valsartan (79) 79
cardiovascular disease (78) 78
proportional hazards models (75) 75
adult (74) 74
analysis (71) 71
heart failure - epidemiology (71) 71
hospitalization - statistics & numerical data (71) 71
myocardial-infarction (69) 69
stroke volume (69) 69
enalapril (68) 68
heart failure - diagnosis (68) 68
left-ventricular dysfunction (67) 67
candesartan (66) 66
ejection fraction (66) 66
heart diseases (66) 66
patient outcomes (66) 66
heart failure - complications (65) 65
patients (65) 65
randomized controlled trials as topic (65) 65
clinical medicine (64) 64
prospective studies (63) 63
time factors (63) 63
heart-failure (62) 62
angiotensin (61) 61
internal medicine (61) 61
myocardial infarction (61) 61
angiotensin ii type 1 receptor blockers - therapeutic use (60) 60
association (59) 59
management (59) 59
klinisk medicin (58) 58
research (57) 57
stroke volume - physiology (57) 57
heart (56) 56
stroke (56) 56
cardiovascular diseases (55) 55
prevalence (55) 55
risk assessment (55) 55
chronic disease (53) 53
diagnosis (52) 52
disease (52) 52
hypertension (52) 52
atrial fibrillation (51) 51
cardiology (50) 50
epidemiology (50) 50
heart attack (49) 49
myocardial infarction - complications (49) 49
incidence (47) 47
dose-response relationship, drug (45) 45
dysfunction (45) 45
heart failure - therapy (45) 45
cardiology and cardiovascular medicine (44) 44
benzimidazoles - therapeutic use (43) 43
drug therapy, combination (43) 43
heart failure - blood (43) 43
acute myocardial-infarction (42) 42
biomarkers - blood (42) 42
randomized-trial (42) 42
angiotensin receptor antagonists - therapeutic use (41) 41
comorbidity (41) 41
kaplan-meier estimate (41) 41
survival rate - trends (41) 41
retrospective studies (40) 40
studies (40) 40
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1047) 1047
Norwegian (2) 2
Polish (2) 2
Spanish (2) 2
Chinese (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 22, pp. 2089 - 2099
Dalcetrapib, an inhibitor of cholesteryl ester transfer protein, raises HDL cholesterol levels. In this clinical trial involving patients with an acute... 
TRIAL | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CARDIOVASCULAR EVENTS | STATIN THERAPY | SAFETY | HIGH-RISK | CHOLESTEROL EFFLUX | PREVENTION | HDL CHOLESTEROL | HIGH-DENSITY-LIPOPROTEIN | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Biomarkers - blood | Apolipoproteins - blood | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Sulfhydryl Compounds - adverse effects | Anticholesteremic Agents - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - mortality | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Female | Aged | Blood Pressure - drug effects | Sulfhydryl Compounds - therapeutic use | C-Reactive Protein - analysis | Measurement | Cholesterol, HDL | Patient outcomes | Dosage and administration | Research | Acute coronary syndrome | Drug therapy | Health aspects | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | C-reactive protein | Heart attacks | Mortality | Cardiovascular disease | Angina | Coronary artery disease | Cholesterol | Cholesteryl ester transfer protein | Studies | Ischemia | Diet | Biomarkers | Blood pressure | Acute coronary syndromes | Cardiovascular diseases | Heart diseases | Lipoproteins (high density)
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 1, pp. 41 - 51
Journal Article
The American heart journal, ISSN 0002-8703, 2010, Volume 159, Issue 3, pp. 331 - 339
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 63, Issue 5, pp. 447 - 456
Objectives This study sought to determine the frequency and magnitude of impaired systolic deformation in heart failure with preserved ejection fraction... 
Cardiovascular | Internal Medicine | systolic strain | cardiac biomarkers | mechanics | diastolic heart failure | echocardiography | BRAIN NATRIURETIC PEPTIDE | CARDIAC RESYNCHRONIZATION THERAPY | MYOCARDIAL-INFARCTION | CONTRACTILITY | SOCIETY-OF-CARDIOLOGY | ABNORMALITIES | SPECKLE TRACKING ECHOCARDIOGRAPHY | DEFORMATION | LEFT-VENTRICULAR FUNCTION | DIASTOLIC DYSFUNCTION | CARDIAC & CARDIOVASCULAR SYSTEMS | ECHOCARDIOGRAPHY | DYSFUNCTION | HYPERTENSION | EPIDEMIOLOGY | VELOCITIES | PATHOPHYSIOLOGY | Prognosis | Prospective Studies | Follow-Up Studies | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Valine - analogs & derivatives | Heart Failure - physiopathology | Stroke Volume - physiology | Male | Echocardiography, Doppler, Color - methods | Aminobutyrates - therapeutic use | Heart Failure - drug therapy | Heart Ventricles - physiopathology | Heart Ventricles - ultrastructure | Neprilysin - antagonists & inhibitors | Aged, 80 and over | Female | Tetrazoles - therapeutic use | Valine - therapeutic use | Ventricular Function, Left - physiology | Aged | Heart Failure - diagnostic imaging | Heart failure | Sects | Hypertension | Heart attacks | Mortality | Medical records | Cardiovascular disease | Hospitalization | Family medical history | Fractions | Hospitals | Womens health | Diabetes | Cardiology | Age
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 20, pp. 1956 - 1964
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 68, Issue 22, pp. 2425 - 2436
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2010, Volume 362, Issue 3, pp. 228 - 238
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2020, Volume 382, Issue 17, pp. 1653 - 1659
The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors... 
CONVERTING ENZYME 2 | MEDICINE, GENERAL & INTERNAL | OLMESARTAN | EXPERIMENTAL AUTOIMMUNE MYOCARDITIS | HEART-FAILURE | DOWN-REGULATION | ACE2 EXPRESSION | FUNCTIONAL RECEPTOR | SARS-CORONAVIRUS | HYPERTENSIVE PATIENTS | MODULATION | Pandemics | Down-Regulation | Humans | Angiotensin Receptor Antagonists - pharmacology | Hypertension - drug therapy | Renal Insufficiency, Chronic - complications | Betacoronavirus - metabolism | Renal Insufficiency, Chronic - drug therapy | Pneumonia, Viral - metabolism | Coronavirus Infections - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Pneumonia, Viral - complications | Peptidyl-Dipeptidase A - metabolism | Coronavirus Infections - complications | Hypertension - complications | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Angiotensin Receptor Antagonists - therapeutic use | Control | Physiological aspects | Development and progression | Research | Renin-angiotensin system | ACE inhibitors | Risk factors | Hypertension | Enzymes | Peptides | Risk groups | Cardiovascular disease | Coronaviruses | Aldosterone | Angiotensin-converting enzyme 2--ACE2 | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Proteins | Renin | Illnesses | Lungs | Peptidyl-dipeptidase A | Coronary vessels | Angiotensin | Physiology | Viral infections
Journal Article